Sponsor content
69 result(s) found, displaying 1 to 10
-
Prescription medicine decision summaryFetroja has been approved for the treatment of infections due to proven or strongly suspected carbapenem-resistant aerobic Gram-negative organisms in adults with limited treatment options. It has specifically been approved for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Fetroja contains the active ingredient cefiderocol (as sulfate tosilate).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MSN TOFACITINIB tofacitinib (as citrate) 10 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TOFADOZ tofacitinib (as citrate) 5 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TOFADOZ tofacitinib (as citrate) 10 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TOFACITINIB LUPIN tofacitinib (as citrate) 5 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MSN TOFACITINIB tofacitinib (as citrate) 5 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TOFACITINIB LUPIN tofacitinib (as citrate) 10 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HARUROPI ropinirole (as hydrochloride) 4 mg/24 hr transdermal drug delivery system sachet.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HARUROPI ropinirole (as hydrochloride) 10 mg/24 hr transdermal drug delivery system sachet.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HARUROPI ropinirole (as hydrochloride) 6 mg/24 hr transdermal drug delivery system sachet.